The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page

Similar documents
NATIONAL QUALITY FORUM Renal EM Submitted Measures

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation

Objectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

Prevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis Adequacy

Applying clinical guidelines treating and managing CKD

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

Patient Description and Diagnosis: Sarah Jones is a 50-year-old female, 5 4, 131

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Validity of the use of Schwartz formula against creatinine clearance in the assessment of renal functions in children

Echocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease

State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE

Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary -trace protein

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

Introduction. 1. Introduction

Advances in Peritoneal Dialysis, Vol. 29, 2013

PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE

HIHIM 409 7/26/2009. Kidney and Nephron. Fermamdo Vega, M.D. 1

Chronic Kidney Disease. Basics of CKD Terms Diagnosis Management

Incremental Hemodialysis

Comparison of Serum Cystatin C and Creatinine Levels to Evaluate Early Renal Function after Kidney Transplantation

The Effect of High-Flux Hemodialysis on Dialysis-Associated Amyloidosis

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Evaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients

Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1

HEALTHYSTART TRAINING MANUAL. Living well with Kidney Disease

Special Challenges and Co-Morbidities

SAMPLE. Chronic Kidney Disease, Evidence-Based Practice, and the Nutrition Care Process. Chapter 1

β-trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

Dr.Nahid Osman Ahmed 1

There are no shortcuts to Dialysis

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC

Evidence Table. Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis.

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Identifying and Managing Chronic Kidney Disease: A Practical Approach

RENAL FUNCTION ASSESSMENT ASSESSMENT OF GLOMERULAR FUNCTION ASSESSMENT OF TUBULAR FUNCTION

Chronic Kidney Disease: Optimal and Coordinated Management

WHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington

Professor Suetonia Palmer

ANEMIA & HEMODIALYSIS

17 th Annual Meeting of JSHDF, Sept 3-4, 2011

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

AJNT. Original Article

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist

Life Science Journal 2014;11(10)

CHRONIC KIDNEY DISEASE WHY WOMEN MAY BE AT RISK?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

HIV AND CHRONIC KIDNEY DISEASE. Understanding GFR

Acute Kidney Injury Care in the Chronic Unit

By; Ashraf El Houfi MD MS (pulmonology) MRCP (UK) FRCP (London) EDIC Consultant ICU Dubai Hospital

Acute renal failure Definition and detection

PD In Acute Kidney Injury. February 7 th -9 th, 2013


Dialysis Dose Prescription and Delivery. William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012

Presented by UIC College of Nursing

Chronic Kidney Disease

Morbidity & Mortality from Chronic Kidney Disease

Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012

Filtration and Reabsorption Amount Filter/d

INSPIRED BY LIFE B. BRAUN DIALYZERS

THE KIDNEY AND SLE LUPUS NEPHRITIS

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Case Study #3: Renal Disease

HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW

Ana Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto

End-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology

Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis

Masatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health

Management of early chronic kidney disease

PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

Achieving Equilibrium in ESRD Patients

Understanding. Your Kidneys. Laurie Biel, RN,BSN, CNN The MGH Center For Renal Education March 28, 2016

Chronic Kidney Disease - An Overview

3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane

Primary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources

Welcome to the UK Primary Hyperoxaluria family support day

TABLE OF CONTENTS T-1. A-1 Acronyms and Abbreviations. S-1 Stages of Chronic Kidney Disease (CKD)

Pediatric Nutrition and Kidney Disease

Hemodialysis is a life-sustaining procedure for the treatment of

I. FILL IN THE BLANKS

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Acceptance onto Dialysis Guidelines

Case Study: Chronic Kidney Disease

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

The UK Renal Registry collects national data about the causes and treatment of kidney failure.

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Predictive Factors for Withdrawal from Peritoneal Dialysis: A Retrospective Cohort Study at Two Centers in Japan

Estimating 24-Hour Urine Sodium Level with Spot Urine Sodium and Creatinine

>4000 mg/dl (=20000/(500/100)) >615 mmol/l (=20000/(65*0.5))

Hemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK

Case Studies: Renal and Urologic Impairments Workshop

HUGE EQUATION ACCURACY FOR SCREENING CHRONIC KIDNEY DISEASE: A PROSPECTIVE STUDY

Supplementary Online Content

Transcription:

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1589-1594 Using Serum Beta Trace Protein to Estimate Residual Kidney Function in Hemodialysis Patients Hesham M. El-Sayed, Hussein S. Hussein andahmad M. Elarnosy Nephrology Department, Faculty of Medicine, Ain Shams University Corresponding author: Ahmad M.Elarnosy, Tel:01158445513, email: ahmadelarnosy@gmail.com ABSTRACT Aim of the work: residual kidney function (RKF) in end stage kidney disease (ESKD) patients contributes significantly to solute clearance. This improves survival as well quality of life in these patients. Kidney Diseases Outcomes Quality Initiative (KDOQI) guidelines suggest that hemodialysis (HD) dose can be safely reduced in those with RKF in the form of residual urea clearance (KRU) of 2 ml/min/1.73 m 2 or more. However, measurement of RKU is difficult as it requires regular inter-dialytic urine collections. Simpler methods for measuring KRU and thus RKF are needed. Beta trace protein (BTP)have been proposed as alternative markers of RKF and RKU. Dialysis specific equations to estimate KRU based on serum BTP wererecentlydeveloped. This study aimed to compare measured KRU using inter-dialytic urine collection and estimated KRU using serum BTP.Patients and Methods: we included 60 ESKD patients in this study;they were divided into 2 groups. Group-1(G-1) had daily urine output <500ml and group-2(g-2) haddaily urine output >500ml. We estimated and measured KRU in both groups. Correlation between measured and estimated KRU in each group was done using Pearson correlation coefficient. Results: the estimated and measured KRU was strongly correlated in G-1 with r=0.746 at p<0.01, but it was week in G-2 with r=0.44 and p<0.05.mean bias between estimated and measured KRU was 0.7 ml/min in G-1. In G-2 the mean bias was -0.54mL/min. Conclusion: KRU and thus RKF can be better estimated using serum BTP in patients with urine output >500mL than in patients with daily urine output200-500ml. Keywords:Hemodialysis,Residual,Kidney,Function,Beta-Trace-Proteins. INTRODUCTION Chronic kidney disease (CKD) is a major health issue as it is considered as a major cause of mortality. The risk of mortality increases exponentially with decreasing renal function (1).The Kidney Disease Outcome Quality Initiatives (K/DOQI) classifies CKD into 5 groups according to the glomerular filtration rate (GFR).Stage 5 is End Stage Kidney Disease (ESKD) and patients in this stage require renal replacement therapy(rrt) to carry out some functions of the failed kidneys (2). Table1:CKD staging according to K/DOQI (2) Stage Description Related Items 1 Kidney damage with normal kidney functions 2 Kidney damage with mild reduction of GFR 3 Moderate GFR reduction 4 Severe GFR GFR: ml/min/ m2 >90 Hematuria,prote inuria, Albuminuria 60-90 Hematuria,prote inuria, Albuminuria 30-60 Early renal insufficiency 15-30 Late renal insufficiency reduction 5 Renal failure <15 End-stage-renaldisease Once CKD patients approach ESKD they lose ability to remove uremic toxins and maintain body euvolumia. They should be referred to a nephrologist care. The patient and his family should be educated about the possible RRTs which includes hemodialysis(hd), peritoneal dialysis(pd) and renal transplant (3). Hemodialysis(HD) carry out some functions of the kidneys in ESKD patients.it removes many uremic toxins like urea and creatinine, normalize electrolytes such as potassium, calcium and phosphate as well as removing excess fluid gains between sessions also known as ultrafiltration (4). Residual kidney function(rkf) is the remaining minimal GFR in patients diagnosed as ESKD who require RRT.Patients with RKF suffer less adverse cardiovascular and anemia; they also tend to have better mineral and nutritional control (5). RKF is generally expressed as urinary clearance of urea(kru). Current guidelines recommend assessment of RKF at regular intervals.kru is included in hemodialysis adequacy if it is >2 ml/min (6). However, there are no simple methods for assessing RKF that are similar to GFR estimation from serum creatinine in non dialysis patients. RKF is assessed by timed 24 to 48 hour urine collection with calculation of KRU. Urine collection is difficult and is prone to errors (6). 1589 Received: 19/ 6 /2017 DOI: 10.12816/0040105 Accepted: 28 / 6 /2017

Using Serum Beta Trace Protein Beta trace proteins (BTP) also known as prostaglandin D 2 sythase, is a low molecular weight glycoprotein. Its molecular weight is 23,000 Da and is made of 168 amino acids. BTP is produced mainly in the central nervous system and also by the retina,kidneys,testes and heart, but it is exclusively excreted by the kidneys. Serum concentration of the BTP is highly correlated with measured GFR (7). As HD clearance is minimal for BTP it makes it attractive candidates for measuring RKF. Dialysis specific equation using serum BTP was recently developed to estimate the KRUand thus RKF in HD patients. Bias using this equation was low and precision and accuracy was high (6). This study aimedto compare KRU estimated from the equation using serum pre-dialysis BTP with KRU measured using serum and urinary urea in two groups of ESKD patients who retain RKF, Group- 1(G-1) had urine output <500ml/24 hrs and group- 2(G-2) had urine output >500ml/24 hrs. PATIENTS AND METHODS This study included 60 ESKD patients on HD at the Dialysis and Nephrology Department of the Italian(Umberto-I) Hospital. The patients were divided into 2 groups. Group-1 (G=1) included patients with daily urine output of >500ml. Group-2 (G-2) included those with urine output from 200-500ml. Inclusion criteria 1-ESKD patients at least 18 years old 2-Daily passage of urine: >500ml urine in G-1 and 200-500mL in G-2 Exclusion criteria 1-Patients who were recieved previous kidney transplant 2-Patients who were recieved medication containing corticosteriods Urinary Urea Clearance Measurement and Estimation The KRU was measured in the interdialytic period which averaged around 44 hours. The patients were asked to collect all urine produced during this interdialytic period. Urinary urea nitrogen(uun) concentration and urine volume was calculated. Serum blood ureanitrogen(bun) samples were drawn at the end of the preceding HD session and directly before the next HD. We used the mean of these 2 values for the measurement urinary urea clearance calculations as follows: UUN concentration *Urine Volume /Mean BUN Concentration. Using serum BTP we estimated the urinary urea clearance using the formula: 69xBTP -2.144 (6) x(1.677 in male) Serum BTP assay was done by ELISA technique using reagents of BTP provided by Bioneovan Co., LTD, Beijing China. The kit allows determination of BTP concentration in human serum,cell culture supernates and other biological fluids. This test employs a sandwich enzyme immunoassay method for quantities measurement of serum BTP. The samples are requires to be coagulated at room temperature for 10-20 minutes then centrifugated at 2000-3000 rpm for 20 minutes to remove supernatant.blood samples for serum BTP were taken pre-dialysis immediately before the first HD session. This study was done after approval of ethical board of Ain Shamns univeristy and an informed written consent was taken from each participant in the study. Statistical Analysis We performed a descriptive analysis of the study population as to assess its characteristics to compare it with other HD populations. Correlation between measured urea clearance and serum BTP, serum urea and previous months on dialysis was made.correlation between measured and estimated KRU in each group was done using Pearson correlation coefficient. Bias and level of agreement between measured and estimated KRU was done using Bland-Altman plot. Bias was calculated as the mean difference between measured and estimated KRU. Comparison between the two groups estimated KRU, and the two groups measured KRU was done using independent T-Test. Level of significance was considered highly significant at p<0.01 and significant at p<0.05we performed all analyses using SPSS software. RESULTS The mean age of all patients was 55.5 years, mean age of G-1 was 54.4, while that of G-2 was 57. Males made 66.7% of all patients and 63% in G-1 and 73% in G-2. Several patients were new dialysis patients and median duration of prior dialysis was 9 months overall, 7months in G-1 and 1590

Hesham El-Sayed et al. 16 in G-2. Majority of patients didn't know the cause of their kidney disease, but the leading known cause of ESKD was diabetes(26.7%) then hypertension(16.7%),obstructive uropathy (6.7%) and glomerulnephritis (3.3%). Table2: patients characteristics All n=60 Group1(n=41) Group2(m=19) Age (years) Mean±SD 55.52 ± 11.20 54.4±8.8 57±12.2 Sex Female 20 (33.3%) 15(37%) 5(27%) Male 40 (66.7%) 26(63%) 14(73%) Duration prior of dialysis :months Median(IQR) 9 (4 15) 7(2-13) 16(10-21) Calcium mg/dl Mean±SD 8.29±0.8 8.38±-0.86 8.12±0.58 Phosphate mg/dl Mean±SD 5.22±1.79 5.17±1.73 5.3±1.73 Hemoglobin g/dl Mean±SD 10.34±1.67 10.6±1.8 9.8±1.15 ALP mg/dl Mean±SD 161±12 176±14 126±5 Dry Weight (kg) Mean±SD 71.73 ± 13.85 71±14 Diabetes 16 (26.7%) 11(26%) 5(26%) 72±12 Glomeruloneph 2 (3.3%) 2(4.8%) 0(0%) Cause of ESKD ritis Hypertension 10 (16.7%) 7(17%) 3(15.7) Obstructive 4 (6.7%) 2(7%) 2(10.5%) Unknown/other 28 (46.7%) 19(46%) 9(47%) The KRU was measured using the mean s of Pre-dialysis and Post-dialysis BUN, urine volume and UUN. Estimated KRU was measured using serum BTP. Other determinants of measured and estimated KRU are shown below. Table3: determinant of measured and estimated KRU All (n=60) Group-1 (n=41) Group-2(n=19) Serum BTP: mg/l Mean±SD 5.31 ± 1.07 6.53±1.32 4.73±1.05 Estimated KRU: ml/min Median(IQR) 2.82 (1.95 4.39) 4.02 (1.59-2.3) 1.88 (2.31-5.71) ID Urine volume : ml Mean±SD 1072.33 ± 209.98 1250±295 611±177 Urine collection time: hrs Mean±SD 42.37 ± 4.88 44±5.6 43±2.29 Urine volume:ml/min Mean±SD 0.45 ± 0.14 0.49±0.16 0.6±0.12 Urine Volume/24hrs:ml Mean±SD 626.79 ± 154.43 681±156 337±92 Predialysis BUN :mg/dl Mean±SD 67.25 ± 10.13 64±9.6 71 ± 10 Post dialysis BUN :mg/dl Mean±SD 25 ± 4.5 24±4.14 26.4±4.7 Serum Creatinine Mean±SD 8.26±2.05 7.6±1.55 8.46±2.09 UUN: mg/dl Mean±SD 300.45 ± 57.68 316±60 290±52 Measured KRU: ml/min Median(IQR) 2.36 (1.67 3.64) 3.3 (2.17-4.49) 1.30 (1.08-1.8) Urine out put correlated positively with estimated and measured KRU in G-1 but with only estimated KRU in G-2. Serum BTP and duration of dialysis correlated negatively with measured and estimated KRU in both groups. Serum BUN and creatinine correlated negatively with estimated KRU while hemoglobin(hb) correlated positively with measured KRU in G-1 1591

Using Serum Beta Trace Protein Table4: correlations of Group-1 Estimated KRU: ml/min Measured KRU: ml/min r p-value r p-value Urine volume 0.5091 0.0260* 0.12 0.641 Duration prior of dialysis: months -0.47 0.042* - 0.57 0.017* Predialysis BUN -0.151 0.249-0.286 0.231 Serum BTP: mg/l -0.731** 0.001-0.471* 0.042 HB -0.277 0.252-0.343 0.150 Calcium 0.070 0.771-0.007 0.97 Phosphorous -0.075 0.077 0.64 0.4 ALP 0.067 0.781 0.372 0.116 Creatinine -0.038 0.902-0.486 0.064 Table5: correlations of Group-2 Estimated KRU: ml/min Measured KRU: ml/min r p-value r p-value ID Urine Output 0.3173 0.0432* 0.44 0.003** Duration prior of dialysis: months -0.508 0.001** -0.319 0.040* Predialysis BUN -0.381 0.013* -0.298 0.058 Serum BTP: mg/l -0.812** 0.001** -0.393* 0.011 HB 0.202 0.283 0.330* 0.035* Calcium 0.03.852-0.134 0.407 Phosphorous -0.111 0.402 0.13 0.417 ALP 0.072 0.654 0.152 0.340 Creatinine --0.309* 0.049-0.149 0.382 A strong positive correlation was found between the estimated and measured KRU in G-1 with correlation coefficient of r=0.741 which was significant at p value=<0.01. 1592

Hesham El-Sayed et al. Mean bias between the estimated and measured KRU was 0.7 ml/min with 95% limits of agreement between 3.5mL/min and -1.96mL/min in G-1. In G-2 the mean bias was -0.54mL/min with 95% limits of agreement between 0.75mL/min and -2 ml/min. Figure1 :correlation of measured and estimated KRU in G-1 The correlation in G-2 was weekly positive with correlation coefficientr=0.462 and was significant at p-value=<0.05. Figure2 :correlation of measured and estimated KRU in G-2 Table 6:Bland-Altman plot analysis Group- Mean Bias 0.7 Upper limit of agreement 3.5 1 Group- ml/min -0.54 ml/min 0.75 2 ml/min ml/min Lower Limit of agreement -1.96 ml/min -2 ml/min Comparing the estimated KRU between the 2 groups using T-Test showed t value of 3.06 at p<0.01. Comparing the measured KRU between 2 groups showed t-value is 4.5 at p<0.01. There is a highly significant difference between the estimated and measured KRU in two groups. Table 7: comparison between the two groups t-value p-value Estimated KRU 3.06 <0.01 Measured KRU 4.5 <0.01 DISCUSSION We used Pearson correlation to detect the relationship of the measured KRU and estimated KRU. There was strong positive correlation in G-1 with correlation coefficient r=0.741 which is highly significant at P value of p=<0.001 with weak correlation in G-2 ; the correlation coefficient was r=0.462 which was significant at p<0.05.this means that the estimated KRU was better correlated with the measured KRU in patients who had urine output >500ml/min. In another study using BTP to estimate urea clearance the correlation coefficient was r=0.781 (8). Using Bland-Atman plot, mean bias between the estimated and measured KRU was 0.7 ml/min with 95% limits of agreement between 3.5mL/min and 1.96mL/min in G-1. In G-2 the mean bias was -0.54mL/min with 95% limits of agreement between 0.75mL/min and -2 ml/min. Mean bias between the measured and estimated KRU in the Wong et al.cohort was 0.50 ml/min with 95% limits of agreement from 2.03 to1.04 ml/min (8). 1593

Using Serum Beta Trace Protein Comparing the estimated KRU between the 2 groups using T-Test showed t value of 3.06 at p<0.01. Comparing the measured KRU between the 2 groups showed that t-value was 4.5 at p<0.01. There was a highly significant difference between the estimated and measured KRU in the two groups. CONCLUSION Residual kidney function is important predictor of mortality and morbidity in ESKD patients. Measuring RKF requires urine collection making it difficult. The equation using BTP to estimate RKU and thus RKF correlated strongly with measured RKU in patients with urine output >500 ml/24 hrs and had mean bias of 0.7mL/min but only week correlation was found in patients with 200-500 ml/24 hrs and the mean bias was 0.54 ml/min. There was also a significant difference between the measured and estimated KRU in both groups. REFERENCES 1. Marcello T, Natasha W, Bruce C et al.(2006):chronic kidney disease and mortality risk: A Systematic Review JASN.,17(7 ):2034-204. 2. Andrew S,LeveyK, Yusuke T et al.(2005):definition and classification of chronic kidney disease: A position statement from kidney disease.kidney International J., 67( 6), 2089 2100. 3. Farrington K, Covic A et al.(2017):clinical practice guideline on management of older patients with chronic kidney disease stage 3b or higher. Nephrology Dialysis Transplantation, 32(1): 9-16. 4. Kim B, William O et al. (2000):Kidney failure choosing a treatment that is right for you. National Kidney and Urologic disease Information,(8):2412-2418. 5. Perl J and Bargman J (2009):The importance of residual kidney function for patients on dialysis: a critical review. American Journal of Kidney Diseases, 53(6):1068-1081. 6. Shafi T, Michels W, LeveyA et al. (2016): Estimating residual kidney function in dialysis patients without urine collection. Kidney International, 89(5):1099-1110. 7. White C, Ghazan-Shahi S, Adams Met al. (2015): β-trace protein: a marker of GFR and other biological pathways. American Journal. 65(1):131-146 Diseases, of Kidney 8. Wong J, Sridharan S, Berdeprado Jet al. (2016):Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin. Kidney. 1090-1098 89(5): J., International 1594